Avalo Therapeutics, Inc. (AVTX) insider trading.
In Q3 2026, insiders at Avalo Therapeutics, Inc. reported 22 non-derivative transactions on 12 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $2.0M.
- Transactions
- 22
- Purchases (P)
- 0
- Sales (S)
- 11
- Net shares, P minus S
- -105,971
- Insiders
- 3
- Last filed
- 2026-09-18
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Doyle Mittie | Officer · Chief Medical Officer | 11 | 0 | 5 |
| Sullivan Christopher Ryan | Officer · Chief Financial Officer | 10 | 0 | 5 |
| Riley Jennifer | Officer · Chief Strategy Officer | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-16 | Sullivan Christopher Ryan | M (A) | 12,394 | $9.88 | 52,294 | Form 4 |
| 2026-09-16 | Sullivan Christopher Ryan | S (D) | 12,394 | $16.33 | 39,900 | Form 4 |
| 2026-09-10 | Sullivan Christopher Ryan | M (A) | 10,185 | $8.04 | 50,085 | Form 4 |
| 2026-09-10 | Sullivan Christopher Ryan | S (D) | 10,185 | $17.62 | 39,900 | Form 4 |
| 2026-08-28 | Doyle Mittie | M (A) | 679 | $8.04 | 52,455 | Form 4 |
| 2026-08-28 | Doyle Mittie | S (D) | 679 | $20 | 51,776 | Form 4 |
| 2026-08-18 | Sullivan Christopher Ryan | S (D) | 31,031 | $20.05 | 39,900 | Form 4 |
| 2026-08-18 | Sullivan Christopher Ryan | M (A) | 31,031 | $9.88 | 70,931 | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | S (D) | 3,749 | $19.94 | 39,900 | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | S (D) | 37,945 | $19.85 | 43,649 | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | M (A) | 2,876 | $9.88 | 81,594 | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | M (A) | 37,945 | $9.88 | 78,718 | Form 4 |
| 2026-08-17 | Doyle Mittie | S (D) | 1,000 | $20 | 51,776 | Form 4 |
| 2026-08-17 | Doyle Mittie | M (A) | 1,000 | $12.65 | 52,776 | Form 4 |
| 2026-08-11 | Riley Jennifer | S (D) | 2,655 | $19.59 | 37,041 | Form 4 |
| 2026-08-10 | Doyle Mittie | M (A) | 679 | $8.04 | 52,455 | Form 4 |
| 2026-08-10 | Doyle Mittie | S (D) | 679 | $20 | 51,776 | Form 4 |
| 2026-07-27 | Doyle Mittie | S (D) | 1,000 | $20 | 51,776 | Form 4 |
| 2026-07-27 | Doyle Mittie | M (A) | 1,000 | $12.65 | 52,776 | Form 4 |
| 2026-06-30 | Doyle Mittie | M (A) | 2,875 | $12.65 | 54,651 | Form 4 |
| 2026-06-30 | Doyle Mittie | M (A) | 1,779 | $8.04 | 56,430 | Form 4 |
| 2026-06-30 | Doyle Mittie | S (D) | 4,654 | $20 | 51,776 | Form 4 |
Transaction codes in this quarter
Get AVTX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1534120&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · AVTX company page · Avalo Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Avalo Therapeutics, Inc. (AVTX)?
In Q3 2026, insiders at Avalo Therapeutics, Inc. reported 22 non-derivative transactions on 12 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $2.0M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Avalo Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/avtx.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.